Skip to main content

Table 3 Changes in diastolic function parameters

From: Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study

  Before liraglutide After liraglutide Before placebo After placebo N for treatment effect Treatment effect for liraglutide Treatment effect for placebo Difference (95% CI) p-value
Diastolic function parameters   
 Average E/eʹ 14.53 (5.76) 14.23 (5.55) 15.28 (6.21) 14.5 (5.98) 29 − 0.20 (2.61) − 0.85 (3.44) 0.65 (− 0.86 to 2.16) 0.386
  Lateral eʹ velocity, cm/s 7.02 (2.15) 6.62 (2.11) 6.52 (2.62) 6.85 (1.98) 30 − 0.40 (1.29) 0.33 (1.55) − 0.74 (− 1.32 to − 0.15) 0.016
 Septal eʹ velocity, cm/s 5.34 (1.32) 5.01 (1.37) 5.24 (1.52) 5.3 (1.44) 29 − 0.31 (0.94) − 0.03 (1.05) − 0.28 (− 0.85 to 0.29) 0.326
 Average eʹ, cm/s 6.11 (1.55) 5.62 (1.47) 5.76 (1.72) 5.84 (1.54) 30 − 0.49 (0.96) 0.08 (0.95) − 0.57 (− 1.05 to − 0.08) 0.023
 Peak TR velocity, m/s 2.2 (0.55) 2.09 (0.6) 2.23 (0.52) 2.17 (0.53) 26 − 0.06 (0.49) − 0.09 (0.27) 0.03 (− 0.15 to 0.2) 0.732
 Left atrial volume index, ml/m2 30.36 (9.04) 26.42 (9.34) 29.78 (8.14) 26.77 (8.88) 30 − 3.95 (5.59) − 3.01 (7.9) − 0.94 (− 4.76 to 2.89) 0.621
Other measures of diastolic function and heart rate   
 E/A ratio 1.06 (0.57) 0.89 (0.22) 0.94 (0.25) 1.02 (0.51) 29 − 0.18 (0.51) 0.08 (0.33) − 0.26 (− 0.55 to 0.03) 0.082
 Mitral valve peak E velocity, cm/s 0.83 (0.19) 0.75 (0.16) 0.8 (0.16) 0.78 (0.17) 29 − 0.08 (0.13) − 0.02 (0.12) − 0.06 (− 0.13 to 0.02) 0.142
 Deceleration time, milliseconds 242.55 (49.71) 234.03 (50.97) 247.95 (48.19) 246.83 (61.02) 29 − 9.90 (51.06) 0.07 (58.8) − 9.96 (− 39.78 to 19.85) 0.499
 Heart rate, bpm 67.67 (12.59) 74.28 (13.08) 68.03 (11.56) 68.48 (9.25) 30 6.61 (10.63) 0.45 (8.12) 6.16 (0.79 to 11.54) 0.026
  1. Data are expressed as the mean (SD)